Keywords
Aldosterone synthase inhibitor
Resistant hypertension
Uncontrolled hypertension
Meta-analysis
Categories
How to Cite
Abstract
Background: Baxdrostat is a selective aldosterone synthase inhibitor proposed for the treatment of resistant and uncontrolled hypertension. However, evidence regarding the safety and efficacy of low doses (0.5–1 mg) and high doses (2–4 mg) compared with placebo remains limited.
Methods: Major bibliographic databases were searched for randomized controlled trials (RCTs) through January 2026. Eligible RCTs compared baxdrostat with placebo. Pooled effect estimates were calculated using mean difference (MD) or risk ratio (RR) with 95% confidence intervals (CIs).
Results: Three RCTs involving patients with resistant or uncontrolled hypertension were included. Baxdrostat significantly reduced systolic blood pressure at low dose [MD: −7.81 mmHg (95% CI: −10.28, −5.33); p<0.001] and high dose [MD: −9.85 mmHg (95% CI: −12.02, −7.69); p<0.001]. Diastolic blood pressure was also significantly reduced at low dose [MD: −2.99 mmHg (95% CI: −5.11, −0.87); p=0.006] and high dose [MD: −4.18 mmHg (95% CI: −5.50, −2.86); p<0.001]. Baxdrostat decreased serum aldosterone and eGFR and increased plasma renin activity, serum potassium, adverse events, and hyperkalemia risk.
Conclusions: Compared with placebo, baxdrostat lowered systolic and diastolic blood pressure in adults with resistant or uncontrolled hypertension, including a CKD-enriched population. The apparent lack of a dose-response difference is based on indirect subgroup analyses of only three trials and should be considered hypothesis-generating rather than evidence of dose equivalence. Hyperkalemia occurred more frequently with baxdrostat, while other safety outcomes remained imprecise. Larger head-to-head dose-comparison trials are needed.
References
1. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020: 1334 [PMID: 32370572, https://doi.org/10.1161/HYPERTENSIONAHA.120.15026]
2. Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernandez-Alfonso MS, Halimi JM, Jarai Z, Jelakovic B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023: 1874 [PMID: 37345492, https://doi.org/10.1097/HJH.0000000000003480]
3. Fryar CD, Kit B, Carroll MD, Afful J. Hypertension Prevalence, Awareness, Treatment, and Control Among Adults Age 18 and Older: United States, August 2021–August 2023. 2024.
4. Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, Fliser D, Roy-Chaudhury P, Fontana M, Nangaku M, Wanner C, Malik C, Hradsky A, Adu D, Bavanandan S, Cusumano A, Sola L, Ulasi I, Jha V, American Society of N, European Renal A, International Society of N. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024: 473 [PMID: 38570631, https://doi.org/10.1038/s41581-024-00820-6]
5. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, O'Connor A, Perumal K, Rahman M, Steigerwalt S, Teal V, Townsend R, Weir M, Wright JT, Jr., Chronic Renal Insufficiency Cohort Study I. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010: 441 [PMID: 19962808, https://doi.org/10.1053/j.ajkd.2009.09.014]
6. Azizi M, Riancho J, Amar L. Aldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases. J Clin Endocrinol Metab. 2025: e557 [PMID: 39656736, https://doi.org/10.1210/clinem/dgae823]
7. Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023: 108 [PMID: 36266539, https://doi.org/10.1038/s41440-022-01070-4]
8. Centers for Disease C, Prevention. Hypertension Prevalence in the U.S. | Million Hearts®. 2023.
9. Bogman K, Schwab D, Delporte ML, Palermo G, Amrein K, Mohr S, De Vera Mudry MC, Brown MJ, Ferber P. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2). Hypertension. 2017: 189 [PMID: 27872236, https://doi.org/10.1161/HYPERTENSIONAHA.116.07716]
10. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019: l4898 [PMID: 31462531, https://doi.org/10.1136/bmj.l4898]
11. Shamim MA, Gandhi AP, Dwivedi P, Padhi BK. How to perform meta-analysis in R: a simple yet comprehensive guide. The Evidence. 2023: 93 https://doi.org/10.61505/evidence.2023.1.1.6]
12. Prasad M. Introduction to the GRADE tool for rating certainty in evidence and recommendations. Clinical Epidemiology and Global Health. 2024: https://doi.org/10.1016/j.cegh.2023.101484]
13. Dwyer JP, Maklad N, Vedin O, Monyak J, Myte R, Chertow GM, Heerspink HJL, Little DJ. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2026: 299 [PMID: 40913594, https://doi.org/10.1681/ASN.0000000849]
14. Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderang U, Wittes J, Williams B, Bax HTNI. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025: 1363 [PMID: 40888730, https://doi.org/10.1056/NEJMoa2507109]
15. Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ, Brig HTNI. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023: 395 [PMID: 36342143, https://doi.org/10.1056/NEJMoa2213169]
16. Gao Y, Mu X, Pang X. Efficacy and safety of aldosterone synthase inhibitors for uncontrolled hypertension: a meta-analysis of randomized controlled trials and systematic review. Front Pharmacol. 2025: 1664810 [PMID: 41059210, https://doi.org/10.3389/fphar.2025.1664810]
17. Siddiqui R, Nadeem H, Sattar MA, Rehan M, Sheikh DN, Jawed S, Akram A. Efficacy and safety of aldosterone synthase inhibitors in hypertension: A systematic review and meta- analysis. Curr Probl Cardiol. 2024: 102875 [PMID: 39384143, https://doi.org/10.1016/j.cpcardiol.2024.102875]
18. Goh JS, Sohail S, Ayub H, Cheema ZZ, Paray NB, Adikari S, Mesmar A, Atout M, Qazi AR, Aldalqamouni A, Younas B, Rauf MA, Khan MAW, Abouayana A, Abouayana AEA, Hasan A, Shahzad M, Ahmed M, Ahmed R, Ahmed S. Efficacy and Safety of Aldosterone Synthase Inhibitors in Hypertension: A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab. 2025: e70094 [PMID: 40944342, https://doi.org/10.1002/edm2.70094]
19. Lytvyn Y, Kimura K, Peter N, Lai V, Tse J, Cham L, Perkins BA, Soleymanlou N, Cherney DZI. Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition. Circulation. 2022: 450 [PMID: 35862082, https://doi.org/10.1161/CIRCULATIONAHA.122.059150]
20. Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, Heerspink HJL, Hugo C, Nangaku M, Rotter RC, Silva A, Shah SV, Sun Z, Urbach D, de Zeeuw D, Rossing P, group ASiC. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024: 379 [PMID: 38109916, https://doi.org/10.1016/S0140-6736(23)02408-X]
21. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC, Jr., Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA, Sr., Williamson JD, Wright JT, Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018: e127 [PMID: 29146535, https://doi.org/10.1016/j.jacc.2017.11.006]
22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010: 336 [PMID: 20171303, https://doi.org/10.1016/j.ijsu.2010.02.007]
23. Chandler J, Cumpston M, Li T. Cochrane handbook for systematic reviews of interventions:
24. Deeks JJ, Higgins JP, Altman DG, Group CSM. Analysing data and undertaking meta‐analyses. Cochrane handbook for systematic reviews of interventions. 2019: 241
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Ahmed L Youseif, Mohamed Eldahrawy, Abdallah Al Ghnaimat, Alaa Ashraf Mohamed, Mohamed Nabil Hamouda, Karim A Khalil, Ahmed F Younis